Sandra M Swain Selected Research

Sandra M Swain Research Topics

Disease

127	Breast Neoplasms (Breast Cancer) 03/2024 - 06/2002
67	Neoplasms (Cancer) 03/2024 - 06/2002
12	Neutropenia 03/2021 - 08/2004
11	Cardiotoxicity 01/2023 - 06/2003
8	Inflammatory Breast Neoplasms 08/2011 - 12/2002
7	Triple Negative Breast Neoplasms 05/2024 - 11/2008
7	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2006
6	Pathologic Complete Response 03/2024 - 10/2004
6	Heart Failure 01/2023 - 06/2003
6	Diarrhea 12/2022 - 10/2004
6	Left Ventricular Dysfunction 01/2020 - 01/2012
5	Amenorrhea 03/2011 - 12/2006
4	Fatigue 11/2018 - 08/2007
4	Peripheral Nervous System Diseases (PNS Diseases) 01/2018 - 04/2006
4	Hand-Foot Syndrome 09/2015 - 10/2004
4	Noninfiltrating Intraductal Carcinoma (DCIS) 04/2012 - 06/2004
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2023 - 11/2012
3	Disease Progression 01/2020 - 08/2007
3	Hypertension (High Blood Pressure) 12/2017 - 01/2012
3	Mucositis 01/2012 - 10/2004
2	Leukemia 02/2024 - 12/2005
2	Pneumonia (Pneumonitis) 05/2022 - 05/2013
2	Febrile Neutropenia 05/2013 - 01/2012
2	Osteonecrosis (Kienbock's Disease) 07/2012 - 01/2006
1	Anaphylaxis (Anaphylactic Shock) 01/2023
1	Hypersensitivity (Allergy) 01/2023
1	Chronic Disease (Chronic Diseases) 12/2022
1	Interstitial Lung Diseases (Interstitial Lung Disease) 05/2022
1	Inflammation (Inflammations) 11/2021

Drug/Important Bio-Agent (IBA)

45	Trastuzumab (Herceptin)FDA Link 06/2023 - 10/2003
33	Docetaxel (Taxotere)FDA Link 12/2022 - 08/2004
24	pertuzumabIBA 01/2023 - 02/2006
22	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2023 - 06/2003
21	human ERBB2 proteinIBA 01/2023 - 11/2005
18	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2018 - 10/2005
17	Estrogen ReceptorsIBA 10/2020 - 12/2002
16	AnthracyclinesIBA 02/2024 - 10/2003
16	ErbB Receptors (EGF Receptor)IBA 01/2023 - 08/2004
15	Hormones (Hormone)IBA 02/2024 - 12/2006
14	Paclitaxel (Taxol)FDA LinkGeneric 06/2023 - 04/2005
14	Bevacizumab (Avastin)FDA Link 07/2017 - 02/2006
13	Taxoids (Taxanes)IBA 01/2023 - 04/2006
12	B 31IBA 01/2023 - 10/2005
11	Biomarkers (Surrogate Marker)IBA 11/2021 - 12/2002
10	Tamoxifen FDA LinkGeneric 11/2023 - 04/2004
9	Capecitabine (Xeloda)FDA Link 05/2024 - 10/2004
8	taxaneIBA 12/2022 - 12/2005
8	ixabepilone (BMS 247550)FDA Link 06/2008 - 04/2005
6	Progesterone Receptors (Progesterone Receptor)IBA 10/2020 - 06/2007
6	epothilone B (EPO906)IBA 06/2008 - 04/2005
5	Phenobarbital (Luminal)FDA Link 03/2024 - 02/2010
5	Aromatase InhibitorsIBA 02/2024 - 01/2008
5	Lapatinib (GW572016)FDA Link 06/2023 - 11/2013
5	Proteins (Proteins, Gene)FDA Link 11/2021 - 09/2006
5	Tyrosine Kinase InhibitorsIBA 05/2021 - 08/2004
5	Gemcitabine FDA Link 09/2015 - 01/2004
5	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2013 - 02/2006
4	Monoclonal AntibodiesIBA 01/2023 - 01/2012
4	Epothilones (Epothilone)IBA 06/2008 - 04/2006
3	NivolumabIBA 05/2024 - 12/2023
3	Immune Checkpoint InhibitorsIBA 03/2024 - 06/2019
3	Letrozole (Femara)FDA LinkGeneric 02/2024 - 01/2019
3	LigandsIBA 11/2022 - 12/2010
3	Cyclin-Dependent Kinases (cdk Proteins)IBA 11/2018 - 06/2002
3	TubulinIBA 03/2008 - 04/2005
3	Excipients (Suspending Agents)IBA 03/2008 - 04/2006
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2005 - 10/2003
3	alvocidib (flavopiridol)IBA 08/2004 - 06/2002
2	Carboplatin (JM8)FDA LinkGeneric 12/2022 - 01/2017
2	crofelemer (SP-303)IBA 12/2022 - 01/2017
2	Estrogen Receptor alphaIBA 11/2022 - 12/2002
2	DNA (Deoxyribonucleic Acid)IBA 11/2022 - 01/2016
2	Ado-Trastuzumab EmtansineIBA 10/2022 - 02/2021
2	Messenger RNA (mRNA)IBA 10/2016 - 01/2016
2	Epidermal Growth Factor (EGF)IBA 11/2014 - 09/2005
2	Angiogenesis InhibitorsIBA 01/2013 - 02/2012
2	AntibodiesIBA 01/2013 - 01/2012
2	ParaffinIBA 08/2012 - 05/2008
2	Diphosphonates (Bisphosphonates)IBA 07/2012 - 01/2006
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2006 - 12/2005
1	2- benzylidene- 3- (cyclohexylamino)- 2,3- dihydro- 1H- inden- 1- oneIBA 02/2024
1	Antineoplastic Agents (Antineoplastics)IBA 01/2023
1	TRPC6 Cation ChannelIBA 01/2023
1	trastuzumab deruxtecanIBA 05/2022
1	Immunoconjugates (Immunoconjugate)IBA 05/2022
1	Irinotecan (Camptosar)FDA LinkGeneric 03/2021
1	OF 4647IBA 11/2020

Therapy/Procedure

69	Therapeutics 02/2024 - 06/2002
42	Drug Therapy (Chemotherapy) 03/2024 - 10/2003
13	Neoadjuvant Therapy 03/2024 - 10/2004
12	Adjuvant Chemotherapy 10/2020 - 01/2004
5	Aftercare (After-Treatment) 08/2007 - 08/2004
4	Segmental Mastectomy (Lumpectomy) 06/2022 - 03/2011
4	Mastectomy (Mammectomy) 01/2018 - 06/2004
4	Radiotherapy 03/2011 - 10/2004
3	Biological Therapy 11/2013 - 01/2010
2	Combination Drug Therapy (Combination Chemotherapy) 11/2014 - 09/2013
2	Drug Tapering 08/2007 - 10/2004
1	Subcutaneous Injections 01/2023
1	Simple Mastectomy 06/2022